On June 14, the U.S. Food and Drug Administration (FDA) approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b. Read more Read more.
FDA approves new combination vaccine for children
